NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-09-28 18:30இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Subsidiaries Declare ~Rs 25.7 Cr in Dividends to Fischer Medical Ventures
Three wholly owned material subsidiaries of Fischer Medical Ventures Limited have declared substantial dividends upstreaming to the parent. Time Medical International Ventures (India) declared a dividend of Rs. 6.50 crore and FlynnCare Health Innovations declared Rs. 10.00 crore for FY26. Additionally, foreign subsidiary FMV Global Innovation Pte approved an interim dividend of USD 1.1 million (~Rs. 9.2 crore) for FY27. In aggregate, around Rs. 25.7 crore of cash flow is moving up to the parent entity.
உச்சம் நம்பிக்கை
என்ன மாறியதுWholly owned subsidiaries declared aggregate dividends totaling Rs 16.5 crore plus USD 1.1 million to the parent company.
ஏன் இது முக்கியம்Demonstrates strong cash generation and operating profitability at the subsidiary operating level, bolstering the holding company's standalone balance sheet and liquidity.
Time Medical Dividend: Rs. 6,50,00,000FlynnCare Health Dividend: Rs. 10,00,00,000FMV Global Innovation Interim Dividend: USD 1,100,000Total Inflow vs TTM PAT (~Rs 42 Cr): ~61%
📅 குறுகிய காலம்Positive sentiment driver as inter-company cash flows validate the operational profitability of its main healthcare ventures.
📈 நீண்ட காலம்Confirms steady cash extraction capability from key units (Time Medical MRI and FlynnCare), providing resources for future organic growth or direct shareholder returns.
⚠ அபாய எச்சரிக்கைகள்
Foreign currency exchange rate fluctuations on the USD 1.1 million dividend payout
Upstreamed dividends are internal transfers and do not alter consolidated group revenue or profit
👀 கவனிக்க வேண்டியவை
Track standalone cash flow statements and parent-level capital allocation in subsequent quarters to see if these upstream cash flows translate into debt reduction, capex, or retail dividends.
Fischer Medical to Invest ₹50 Cr via Rights Issues in Three Wholly Owned Material Subsidiaries
Fischer Medical Ventures' Board has approved an aggregate cash investment of ₹50.00 Cr to subscribe to rights issues across three wholly owned material subsidiaries. The company will invest ₹11.50 Cr in Time Medical International Ventures, ₹12.50 Cr in FlynnCare Health Innovations, and ₹26.00 Cr in Singapore-based FMV Global Innovation Pte Ltd. The total investment commitment represents approximately 17% of the company's TTM revenue (₹293 Cr) and 9.1% of its current market capitalization (₹548 Cr). All target entities remain 100% owned subsidiaries post-transaction, which will be executed on an arm's length basis backed by registered valuer reports.
உச்சம் நம்பிக்கை
என்ன மாறியதுFischer Medical Ventures committed to inject ₹50.00 Cr in equity into three wholly owned subsidiaries by subscribing to their rights issues.
ஏன் இது முக்கியம்The capital infusion scales its digital healthcare, MRI manufacturing, and international wholesale operations, representing a notable capital redeployment relative to its ₹548 Cr market cap.
Total subsidiary investment: ₹50.00 கோடிInvestment vs Market Cap: ~9.1%Investment vs TTM Revenue: ~17.1%FMV Global Innovation rights price: INR 26,00,00,000Flynncare Health rights price: INR 12,50,00,000Time Medical India rights price: INR 11,50,00,000
📅 குறுகிய காலம்Neutral impact on stock price as this represents internal capital allocation among existing 100% subsidiaries with no immediate change in consolidated financials.
📈 நீண்ட காலம்Strengthens capital bases of key operating entities (digital health platform FlynnCare and global trading unit FMV Singapore), supporting the company's stated expansion in export and preventive healthcare segments.
⚠ அபாய எச்சரிக்கைகள்
Cash drain on parent balance sheet to fund subsidiary working capital/capex
Turnover contraction observed at Time Medical India (from ₹8,273.58 lakhs in FY25 to ₹5,500.05 lakhs in FY26)
👀 கவனிக்க வேண்டியவை
Track the upcoming quarterly balance sheet to monitor cash outflows and funding sources for this ₹50 Cr capital deployment, alongside revenue contributions from the Singapore and FlynnCare arms.
Fischer Medical Ventures Launches CLARION 64/128-Slice AI-Driven CT Scanner System
Fischer Medical Ventures Limited's wholly owned subsidiary, Time Medical International Ventures (TMIV Imaging), has launched its next-generation CLARION 64/128-Slice AI-driven CT system at the India Health Expo 2026. The platform features an advanced Liquid Metal Bearing X-ray tube with 360-degree liquid cooling, an Aegis detector system, and configurations supporting up to 128 slices with a 91 cm bore option. This launch expands the company's radiology equipment portfolio beyond MRI machines into high-end diagnostic and surgical CT imaging.
உச்சம் நம்பிக்கை
என்ன மாறியதுFischer Medical Ventures officially unveiled its commercial CLARION 64/128-slice CT scanner platform in the Indian market.
ஏன் இது முக்கியம்Broadens the company's medical imaging product suite from MRI systems into the high-demand CT scanner segment, aligning with its domestic manufacturing and export growth strategy.
📅 குறுகிய காலம்Showcases portfolio expansion and technology capability; immediate financial impact depends on converting product showcases into hospital procurement orders.
📈 நீண்ட காலம்Strengthens domestic imaging product mix and import-substitution positioning under 'Make-in-India', supporting target revenue diversification.
⚠ அபாய எச்சரிக்கைகள்
Commercial uptake and order pipeline values not yet disclosed
Intense competition from established multinational imaging equipment manufacturers
👀 கவனிக்க வேண்டியவை
Track commercial order traction, manufacturing ramp-up at the AP Medtech Zone facility, and revenue contribution from the new CT platform in upcoming quarterly disclosures.
Fischer Medical Unit Wins Catanduanes Digital Healthcare Project in Philippines
Fischer Medical Ventures Limited's step-down subsidiary, Time Medical Philippines (TM-P), has been awarded a province-wide digital healthcare project in Catanduanes Province, Philippines. The rollout involves deploying health kiosks integrated with the PhilHealth-accredited FlynnCare Clinic Management System across municipalities and barangays. While the contract value was not disclosed, this marks the group's first province-wide integrated healthcare implementation supporting the Philippine Universal Health Care initiative. This aligns with the company's international expansion strategy in Southeast Asia across preventive and digital health platforms.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுTime Medical Philippines secured a province-wide project award to deploy integrated digital health kiosks and clinic software across Catanduanes Province.
ஏன் இது முக்கியம்Demonstrates commercial execution of the company's export market strategy in Southeast Asia, validating its preventive care and digital software integration model.
📅 குறுகிய காலம்Sentiment positive on international project win, but price impact may be tempered given the absence of quantified contract value.
📈 நீண்ட காலம்Serves as a reference deployment for scaling similar municipal and provincial digital healthcare projects across the Philippines and broader SEA markets.
⚠ அபாய எச்சரிக்கைகள்
Contract value and margins not disclosed
Execution and regulatory risks in overseas jurisdiction
Concentration on government-led Universal Health Care rollout timelines
👀 கவனிக்க வேண்டியவை
Track subsequent quarterly financial updates for revenue contributions from Southeast Asian operations and disclosures on contract value or additional provincial rollouts.
Fischer Medical allots 2.05 Cr shares on warrant conversion, raising Rs 35.99 Cr
Fischer Medical Ventures Limited has approved the allotment of 2,05,05,909 equity shares of face value Re 1 each at an issue price of Rs 23.40 per share upon conversion of warrants. The company collected the remaining 75% exercise price of Rs 17.55 per warrant, totaling Rs 35.99 crore in cash. Promoters subscribed to 1,33,35,909 shares (Rs 23.40 crore), while a non-promoter accounted for 71,70,000 shares (Rs 12.58 crore). The inflow represents ~6.2% of the company's Rs 580 crore market capitalization.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company converted 2,05,05,909 share warrants into fully paid equity shares following receipt of the 75% balance consideration.
ஏன் இது முக்கியம்The infusion of Rs 35.99 crore provides fresh equity capital to fund business operations and medical tech initiatives, alongside minor equity dilution.
Shares allotted: 2,05,05,909Issue price per share: Rs 23.4075% Consideration received: Rs 35.99 கோடிInflow vs Market cap: ~6.2%Promoter allotment: 1,33,35,909 பங்குகள்
📅 குறுகிய காலம்The newly issued 2.05 crore shares will be listed and admitted to trading, slightly expanding the equity base while improving liquid cash balances.
📈 நீண்ட காலம்Continued promoter participation (~65% of the conversion) demonstrates insider backing for the company's medtech and preventive healthcare strategy.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from the addition of 2.05 crore shares
Execution risk in deploying funds efficiently to sustain top-line growth
👀 கவனிக்க வேண்டியவை
Track the deployment of the Rs 35.99 crore capital into manufacturing automation and working capital, along with the updated shareholding pattern post-allotment.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Fischer Medical Q1 Standalone Loss Widens to ₹3.5 Cr; Allots 2.05 Cr Shares via Warrants
Fischer Medical Ventures reported a weak standalone Q1 (quarter ended June 30, 2026) with revenue declining to ₹0.72 Cr (₹72.17 lakhs) compared to ₹4.54 Cr in the year-ago period. Standalone net loss widened to ₹3.50 Cr (₹350.41 lakhs) from a loss of ₹0.61 Cr in Q1 FY26. The Board also approved the allotment of 2,05,05,909 equity shares at ₹23.40 per share pursuant to warrant conversions, collecting ~₹35.99 Cr in balance conversion consideration. In addition, two Independent Directors (Mr. Roberto M Pagdanganan and Mr. Sanjay Jayantilal Jain) resigned effective August 14, 2026, prompting a reconstitution of key Board committees.
உச்சம் நம்பிக்கை
என்ன மாறியதுFischer Medical declared widening standalone Q1 losses, expanded its equity base by 2.05 Cr shares via warrant conversion, and reconstituted board committees following two director exits.
ஏன் இது முக்கியம்A sharp drop in standalone revenue combined with elevated finance and overhead expenses stresses profitability, while warrant exercise introduces equity dilution.
Standalone Q1 Revenue: ₹72.17 லட்சம்Standalone Q1 Net Loss: ₹350.41 லட்சம்Shares allotted via warrants: 2,05,05,909Warrant conversion price: ₹23.40 per shareTotal warrant consideration received: ₹35.99 கோடி
📅 குறுகிய காலம்Sentiment is likely to be subdued due to widening standalone losses and simultaneous resignation of two independent directors.
📈 நீண்ட காலம்Growth sustainability depends on operational traction at the AP Medtech Zone facility and scaling consolidated revenues in preventive healthcare and imaging.
⚠ அபாய எச்சரிக்கைகள்
Widening operating loss at standalone level
Equity dilution from conversion of 2.05 Cr warrants
Simultaneous resignation of two Independent Directors
👀 கவனிக்க வேண்டியவை
Track consolidated financial performance to gauge full operating health across subsidiaries, and monitor deployment of the ₹35.99 Cr raised from warrant conversions.
Rs 25.06 Cr raised via conversion of 1.43 Cr warrants by Promoters and Investors
Fischer Medical Ventures has allotted 1,42,78,217 equity shares following the conversion of warrants at an exercise price of Rs 23.40 per share. The company received the remaining 75% payment amounting to Rs 25.06 crore from promoters and one non-promoter fund (Vikasa India Eif I Fund). This capital infusion represents approximately 4.3% of the current market capitalization and strengthens the balance sheet for future growth. The conversion price of Rs 23.40 is at a significant discount to the current market price of Rs 38.8.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company converted outstanding warrants into equity shares, resulting in a cash infusion of Rs 25.06 crore and an increase in the total paid-up equity capital.
ஏன் இது முக்கியம்This provides the company with necessary liquidity to fund its expansion into mental health and wellness screening while demonstrating continued financial commitment from the promoters.
Total Consideration Received (75%): Rs 25.06 கோடிIssue Price per Share: Rs 23.40Total Shares Allotted: 1,42,78,217Fundraise vs Market Cap: ~4.3%Fundraise vs TTM Revenue: ~9.6%
📅 குறுகிய காலம்The stock may see neutral to positive sentiment as the capital infusion is finalized, though the equity dilution is now formal.
📈 நீண்ட காலம்The additional capital supports the company's structural shift toward higher-margin preventive healthcare solutions and export market expansion.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of approximately 9-10%
Conversion price is significantly lower than the current market price
👀 கவனிக்க வேண்டியவை
Investors should monitor the deployment of these funds toward the company's goal of a 50/50 revenue split between Imaging and Preventive Healthcare and its 'Make-in-India' initiatives.
Rs 11.64 Cr raised as Fischer Medical allots 66.31 lakh shares to Promoters via warrant conversion
Fischer Medical Ventures has allotted 66,31,664 equity shares to its promoters following the conversion of warrants. The company received the remaining 75% of the exercise price, totaling Rs 11.64 crore in cash. The shares were issued at Rs 23.40 each, which represents a significant discount to the current market price of Rs 37.7. This capital infusion by the promoters demonstrates continued commitment to the company's growth strategy in the medical equipment sector.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company converted 66.31 lakh warrants into equity shares, resulting in a cash inflow of Rs 11.64 crore and an increase in the total paid-up equity capital.
ஏன் இது முக்கியம்This provides the company with additional liquidity to fund its expansion into preventive healthcare and mental health screening, while signaling promoter confidence in the business's long-term value.
📅 குறுகிய காலம்The news is likely to be viewed positively by the market as it confirms promoter backing and provides immediate cash flow, though the equity dilution is a factor to consider.
📈 நீண்ட காலம்The capital supports the company's goal of a 50/50 revenue split between Imaging and Preventive Healthcare, which is expected to drive higher margins over the next 3 years.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution for minority shareholders
Issue price is at a ~38% discount to current market price
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming shareholding pattern to see the exact increase in promoter stake and watch for management commentary on the utilization of these funds for their 'Make-in-India' initiatives.
First Installation: Fischer Medical Subsidiary Partners for AI-Enabled iMRI Suite in Vadodara
Fischer Medical Ventures Limited, through its subsidiary Time Medical India, has announced its first partnership to install the DRIS–iMRI Medharanya Suite at Parul Sevashram Hospital, Vadodara. This AI-enabled portable intraoperative MRI system provides real-time visualization during complex neurosurgeries, integrating AR, ML, and Exoscope technologies. While the specific contract value was not disclosed, the partnership leverages Parul University's ecosystem of 43,000+ students for clinical validation. This move aligns with the company's strategy to scale its imaging segment, which contributed to a 120% revenue growth in H1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுFischer Medical has moved from the development phase to the first clinical deployment of its specialized intraoperative MRI technology in India.
ஏன் இது முக்கியம்This installation serves as a critical reference site for the company's high-margin imaging segment. Successful deployment at a major teaching hospital validates the technology and supports the company's goal to achieve a 50/50 revenue split between Imaging and Preventive Healthcare.
TTM வருவாய்: ₹260 கோடிPartner University Student Base: 43,000+Order Value: வெளியிடப்படவில்லைTTM PAT: ₹39 கோடி
📅 குறுகிய காலம்The announcement is likely to be viewed positively as it demonstrates technological progress and institutional acceptance of their 'Make-in-India' MRI solutions.
📈 நீண்ட காலம்If the company successfully scales these specialized MRI suites across its target MENA and SEA markets, it could significantly improve operating margins and structural positioning in the high-end medical equipment space.
⚠ அபாய எச்சரிக்கைகள்
Lack of disclosed financial value for the partnership
Execution risk associated with the first-time installation of complex medical hardware
High competition from established global radiology equipment manufacturers
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful commissioning of this suite and look for subsequent orders from other medical institutions to gauge the commercial scalability of this high-tech product. The ability to convert this 'first-of-its-kind' installation into a recurring order book will be key to achieving the company's 15-20% growth target.
Fischer Medical Secures CDSCO Approval for Spincare; Targets $380M Indian Wound Care Market
Fischer Medical Ventures' associate company, Nanomedic Technologies (Israel), has received CDSCO Class C import approval for the Spincare Portable Wound Care System. Fischer holds exclusive distribution rights for this first-of-its-kind electrospun technology across India and Southeast Asia. The Indian wound care market is valued at $380 million in 2026 and is projected to reach $1.8 billion by 2033. This regulatory milestone allows the company to begin commercial deployment in hospitals and burn centers, diversifying its revenue stream beyond medical imaging.
உச்சம் நம்பிக்கை
என்ன மாறியதுFischer Medical has transitioned from a regulatory waiting phase to having full legal clearance to import and distribute a unique, portable wound care system in India.
ஏன் இது முக்கியம்This represents a major step in the company's strategy to achieve a 50/50 revenue split between Imaging and Preventive Healthcare. It grants Fischer entry into a high-growth, high-margin medical device niche with exclusive regional rights.
India Wound Care Market (2026): USD 380 millionProjected India Market (2033): USD 1.8 billionSEA Market Projection (2030): USD 354 millionTTM வருவாய்: Rs 260 கோடிProduct Shelf Life: 5 years
📅 குறுகிய காலம்The stock may see positive sentiment as this approval validates the company's expansion into advanced medical technologies and opens a new revenue channel.
📈 நீண்ட காலம்If successfully executed, this product could significantly contribute to the company's 15-20% growth target and re-rate the business as a diversified med-tech provider rather than just an imaging company.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in establishing a new sales network for wound care
Dependency on Israeli associate for product supply
Competition from traditional wound dressing manufacturers
👀 கவனிக்க வேண்டியவை
Monitor the timeline for the first commercial orders and hospital tie-ups in India. Watch for the outcome of the pending US FDA approval application by the associate company, which would serve as a global quality benchmark.
Fischer Medical Ventures FY26 Net Profit Surges to ₹31.02 Cr; Recommends ₹0.05 Dividend
Fischer Medical Ventures reported a massive turnaround for the full year ended March 31, 2026, with consolidated revenue jumping to ₹308.58 crore from ₹110.70 crore in the previous year. Annual consolidated net profit skyrocketed to ₹31.02 crore compared to just ₹1.21 crore in FY25. Despite the strong annual performance, the company recorded a consolidated net loss of ₹7.12 crore in Q4 FY26. The Board has recommended a final dividend of ₹0.05 per equity share.
முக்கிய அம்சங்கள்
Consolidated annual revenue from operations grew by 178.7% YoY to ₹30,857.56 Lakhs.Full-year consolidated net profit increased significantly to ₹3,101.94 Lakhs from ₹120.79 Lakhs in FY25.Board recommended a final dividend of ₹0.05 per equity share for FY 2025-26.Consolidated Basic EPS improved to ₹0.48 for FY26 from ₹0.02 in the previous year.The company reported a consolidated net loss of ₹711.94 Lakhs in Q4 FY26 against a profit of ₹131.22 Lakhs in Q4 FY25.
👀 கவனிக்க வேண்டியவை
Investors should view the massive annual growth and turnaround as a strong positive, though the Q4 loss warrants a closer look at operating margins and expense spikes. The initiation of a dividend is a positive signal of management's confidence in cash flows.
Fischer Medical FY26 Consolidated Net Profit Surges to ₹31.02 Cr; ₹0.05 Dividend Declared
Fischer Medical Ventures reported a massive 186% year-on-year increase in consolidated total income for FY26, reaching ₹32,088.93 Lakhs. The annual consolidated net profit saw a significant jump to ₹3,101.94 Lakhs compared to just ₹120.79 Lakhs in FY25. Despite the strong annual performance, the company recorded a consolidated net loss of ₹709.78 Lakhs in Q4 FY26, primarily driven by a sharp increase in other expenses. The board has also recommended a final dividend of ₹0.05 per equity share.
முக்கிய அம்சங்கள்
Consolidated FY26 Total Income rose to ₹32,088.93 Lakhs from ₹11,219.07 Lakhs in FY25.Full-year Consolidated Net Profit increased significantly to ₹3,101.94 Lakhs from ₹120.79 Lakhs YoY.Board recommended a final dividend of ₹0.05 per equity share (Face Value ₹1).Q4 FY26 consolidated results showed a net loss of ₹709.78 Lakhs versus a profit of ₹131.22 Lakhs in Q4 FY25.Standalone FY26 performance reported a net loss of ₹1,042.29 Lakhs, indicating most value resides in subsidiaries.
👀 கவனிக்க வேண்டியவை
The massive consolidated growth suggests the company's transition into medical ventures is scaling rapidly, though investors should investigate the cause of the Q4 loss and high 'Other Expenses'. Monitor the sustainability of subsidiary profits as the standalone entity remains loss-making.
Fischer Medical Subsidiary Signs Landmark Global Neurosurgical Tech Partnership with WFNS
Fischer Medical Ventures' subsidiary, Time Medical India, has secured a historic partnership with the WFNS Innovation & Technology Committee. This is the first time the WFNS committee has formally partnered with a private industry participant to advance global neurosurgical innovation. The collaboration will focus on high-end medical imaging, including intraoperative MRI suites and specialized brain aneurysm screening technologies. This strategic alliance enhances the company's global standing and provides a platform for disseminating its advanced diagnostic solutions worldwide.
முக்கிய அம்சங்கள்
First-ever industry partnership formally established by the WFNS Innovation & Technology Committee.Focus on advanced technologies including single-room intraoperative MRI and Exoscope visualization.Collaboration covers global training, knowledge-sharing, and technology transfer initiatives for neurosurgical care.Targets improved precision and patient outcomes in neuro-imaging across both emerging and developed markets.
👀 கவனிக்க வேண்டியவை
This partnership provides significant global validation for Fischer’s medical technology; investors should monitor how this association translates into international order book growth and market penetration.
Fischer Medical Allots 60 Lakh Shares to Promoter; Raises Rs 10.53 Cr via Warrant Conversion
Fischer Medical Ventures Limited has approved the allotment of 60,00,000 equity shares to its promoter, Mr. Shankar Varadharajan, following the conversion of warrants. The shares were issued at a price of Rs. 23.40 per share, which includes a premium of Rs. 22.40. The company received a total cash consideration of Rs. 10.53 crores, representing the final 75% payment required for the conversion. This move increases the promoter's equity stake and provides the company with fresh growth capital.
முக்கிய அம்சங்கள்
Allotment of 60,00,000 equity shares of face value Re. 1 eachIssue price of Rs. 23.40 per share, including a premium of Rs. 22.40Total consideration of Rs. 10,53,00,000 received for the remaining 75% exercise priceAllottee is Mr. Shankar Varadharajan, belonging to the Promoter categoryConversion completed via Circular Resolution dated March 31, 2026
👀 கவனிக்க வேண்டியவை
Investors should view the promoter's decision to exercise warrants as a strong signal of confidence in the company's valuation and future growth. The capital infusion of over Rs. 10 crore should be monitored for its impact on upcoming medical technology projects.
Fischer Medical Ventures Subsidiary Acquires 75% Stake in Indonesian Medical Firm
Fischer Medical Ventures Limited's wholly owned subsidiary, FMV Global Innovations Pte Limited, has acquired a 75% stake in PT Fischer Pariko Medical Ventures. The target entity is a newly incorporated Indonesian company focused on the wholesale of medical, scientific, and precision equipment. As the entity was incorporated in October 2024, it reported nil turnover for the 2024-25 period. This acquisition marks a strategic expansion for Fischer Medical into the Southeast Asian healthcare market.
முக்கிய அம்சங்கள்
Acquisition of 75% stake in PT Fischer Pariko Medical Ventures via a 100% owned subsidiary.Target entity is based in Indonesia and operates in the healthcare and medical equipment wholesale industry.The acquired company is a startup incorporated on October 14, 2024, with nil revenue for FY24-25.The move signifies an international expansion strategy into the Indonesian medical equipment market.
👀 கவனிக்க வேண்டியவை
Investors should monitor the operational progress of this new Indonesian venture as it begins generating revenue. While the acquisition is strategic, the target is a startup, so immediate financial impact will be limited.
Fischer Medical Launches India's First Helium-Free 1.5T MRI Platforms MICA and QUIN
Fischer Medical Ventures Limited, through its subsidiary Time Medical India, has launched two advanced 1.5T MRI platforms, MICA and QUIN, at IRIA 2026. QUIN is distinguished as India's first helium-free 1.5T wide 70 cm bore MRI system, which eliminates helium dependency and simplifies installation. Both systems have secured CDSCO certification, allowing for immediate commercial rollout in the Indian healthcare market. These launches represent a significant technological milestone for the company in the sustainable medical imaging sector.
முக்கிய அம்சங்கள்
Launched QUIN, India's first helium-free 1.5T wide 70 cm bore MRI system.Introduced MICA, a 1.5T 32-channel MRI with 1000-litre zero boil-off magnet technology.Both MRI platforms have received mandatory CDSCO certification for the Indian market.QUIN features a no-quench-pipe auto ramp unit, reducing infrastructure requirements.Systems are available in 32 and 64-channel configurations for high-resolution imaging.
👀 கவனிக்க வேண்டியவை
The launch of India's first helium-free MRI technology positions Fischer as a leader in cost-effective medical imaging. Investors should watch for order book growth and hospital partnerships following this launch.
Fischer Medical Subsidiary Secures Rs 40 Crore Loan from HDFC Bank
Fischer Medical Ventures' material subsidiary, Time Medical International Ventures (India) Private Limited, has entered into a secured loan agreement with HDFC Bank for Rs 40 Crores. The loan carries an interest rate of 3 months Repo plus 2.75% per annum. The facility is secured by a pledge of shares and Fixed Deposit collateral. This capital infusion will likely support the subsidiary's operational requirements or growth initiatives.
முக்கிய அம்சங்கள்
Loan amount of Rs 40 Crores sanctioned by HDFC Bank to the material subsidiary.Interest rate set at 3 months Repo rate + 2.75% per annum.Loan is secured through pledged shares and Fixed Deposit (FD) collateral.Agreement approved by the Board of Directors on January 30, 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization of these funds and the subsequent impact on the subsidiary's revenue growth. The debt addition is manageable given the secured nature and competitive interest pricing.
Fischer Medical Q3 FY26 Consolidated Revenue Surges to ₹101 Cr; PAT at ₹19.2 Cr
Fischer Medical Ventures reported a massive jump in consolidated revenue to ₹10,109.52 Lakhs for Q3 FY26, compared to ₹1,174.85 Lakhs in the same quarter last year. The company turned profitable on a consolidated basis with a PAT of ₹1,923.48 Lakhs, a significant recovery from a loss of ₹29.39 Lakhs in Q3 FY25. For the nine-month period, consolidated revenue reached ₹21,084.52 Lakhs, marking a substantial growth over the previous year's ₹6,152.45 Lakhs. However, the standalone business reported a loss of ₹166.93 Lakhs for the quarter, indicating that growth is heavily driven by its subsidiaries.
முக்கிய அம்சங்கள்
Consolidated revenue grew by approximately 760% YoY to ₹10,109.52 Lakhs in Q3 FY26.Consolidated PAT turned positive at ₹1,923.48 Lakhs versus a loss of ₹29.39 Lakhs in the previous year's quarter.Nine-month consolidated PAT stands at ₹3,813.89 Lakhs compared to a loss of ₹10.42 Lakhs in the prior period.Board approved restructuring of Malaysian subsidiary Fischer Hospitality Sdn. Bhd. with a trustee holding 51%.Company Secretary and Compliance Officer Mr. Aravindkumar V resigned effective February 10, 2026.
👀 கவனிக்க வேண்டியவை
The massive consolidated growth and turnaround to profitability are strong positive signals, though investors should note that the standalone entity remains in a loss. Monitor the appointment of the new Compliance Officer and the progress of the Malaysian subsidiary restructuring.
Fischer Medical Ventures enters Indonesia for TB Eradication
Fischer Medical Ventures Limited, through its subsidiary Time Medical International Ventures (India) Pvt Ltd, is entering Indonesia via a TB eradication partnership with the City of Jember. This collaboration involves PT Pariko and includes a pilot deployment of 250 AI-powered X-ray systems by March 2026. The order size is approximately USD 6.5 million, positioning FMV as a strategic partner in Indonesia’s public healthcare initiatives. This expansion could positively impact the company's revenue stream in the coming years.
முக்கிய அம்சங்கள்
Time Medical International Ventures (India) Pvt Ltd enters IndonesiaPilot deployment of 250 units of AI-powered X-ray systems planned by March 2026Order size is approximately USD 6.5 millionPartnership with the City of Jember for TB eradication
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the pilot deployment and the potential for further expansion in Indonesia. Keep an eye on revenue growth related to this international venture.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
